Evidence map›Paper›PMID 27377904›Full record

ArticleJournal of the National Cancer Institute2016

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Sinead Toomey, Alex J Eustace, Laura B Pritzker, Ken P H Pritzker, Joanna Fay, Anthony O'Grady, Robert Cummins, Liam Grogan, John Kennedy, Darran O'Connor and 7 more

Registry-linked trialAbstract readLetterComment

PubMed Full text at PMC Publisher

In one paragraph

Article in Journal of the National Cancer Institute, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03524430 (RNA Disruption Assay), which is not on this map. Cited by 9 papers.

0numbers the graph read from it

0cells of the map it votes in

9citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03524430 naactive not recruitingnot on this mapstarted 2018, after this paper: background citation

RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy (BREVITY / BREVITY-02 in Germany)

TypeinterventionalSponsorRna Diagnostics Inc.Ran2018 to 2031Enrolled801ConditionsBreast Neoplasm FemaleArmsCore needle biopsy

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy.Breast cancer research : BCR · 2025
Trial
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
Trial
Ribosomal RNA Degradation (RNA Disruption) in Tumour Cells: Mechanistic Insights and Potential Clinical Utility.Cancers · 2025
Review
Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study).BMC cancer · 2024
Article
Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer.JNCI cancer spectrum · 2024
Article
RNA disruption is a widespread phenomenon associated with stress-induced cell death in tumour cells.Scientific reports · 2023
Article
The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer.Breast cancer research and treatment · 2021
Article
Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review.OncoTargets and therapy · 2020
Review
RNA disruption indicates CHOP therapy efficacy in canine lymphoma.BMC veterinary research · 2019
Article

4 · The record

Corrections and comments

Commented on by
Response.2016
Comment on
RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy.2015

5 · Who and what money

Authors and funding

17 authors.

Sinead ToomeyMedical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH).

Alex J EustaceMedical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH). alexeustace@rcsi.ie.

Laura B PritzkerMedical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH).

Ken P H PritzkerMedical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH).

Joanna FayMedical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH).

Anthony O'GradyMedical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH).

Robert CumminsMedical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH).

Liam GroganMedical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH).

John KennedyMedical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH).

Darran O'ConnorMedical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH).

Leonie YoungMedical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH).

Elaine W KayMedical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH).

Norma O'DonovanMedical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH).

William M GallagherMedical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH).

Roshni KalachandMedical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH).

John CrownMedical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH).

Bryan T HennessyMedical Oncology Group, Dept. of Molecular Medicine (ST, AJE, RK, BTH), Department of Pathology (JF, AO, RC, EK), Molecular and Cellular Therapeutics (DO), and Endocrine Oncology Research Group, Department of Surgery (LY), Royal College of Surgeons in Ireland, Dublin, Ireland; RNA Diagnostics Inc., Toronto, Ontario, Canada (LBP, KPHP); Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada (KPHP); Department of Oncology, Beaumont Hospital, Dublin, Ireland (LG, BTH); Department of Oncology, St. James Hospital, Dublin, Ireland (JK); Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland (NO, JC); School of Biomolecular & Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland (WMG); Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland (JC); All Ireland Clinical Oncology Research Group (BTH).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Neoadjuvant TherapyTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesHumansRNAERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesRNATrastuzumab

Identifiers

PMID27377904

DOI10.1093/jnci/djw111

PMCPMC5017949

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

NCT03524430ClinicalTrials.gov

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.